MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5416-5427

  Wang, Lin ^a   Shi, Zhu mei ^a,b   Jiang, Cheng fei ^a   Liu, Xue ^a   Chen, Qiu dan ^a   Qian, Xu ^a   Li, Dong mei ^a   Ge, Xin ^a   Wang, Xie feng ^b   Liu, Ling Zhi ^c   You, Yong ping ^b   Liu, Ning ^b   Jiang, Bing Hua ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Glioma; miR 143; N RAS; Tumor growth

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 143; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SYNAPTOTAGMIN I; TEMOZOLOMIDE; VASCULOTROPIN; ALKYLATING AGENT; DACARBAZINE; MICRORNA; MIRN143 MICRORNA, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL DESTRUCTION; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; N RAS GENE; NEUROBLASTOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRUS ONCOGENE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NUDE MOUSE; ONCOGENE RAS; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DOWN-REGULATION; GENES, RAS; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906269494     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2116     Document Type: Article

References (54)

1. Reardon DA, Rich JN, Friedman HS and Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006; 24(8):1253-1265.
2. Hoelzinger DB, Demuth T and Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst. 2007; 99(21):1583-1593.
3. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001; 2(2):120-129.
4. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001; 15(11):1311-1333.
5. Sanai N, Alvarez-Buylla A and Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005; 353(8):811-822.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-996.
7. Zhu Y and Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer. 2002; 2(8):616-626.
8. Wen PY and Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
9. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD and Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-oncology. 2011; 13(4):384-392.
10. Ambros V and Lee RC. Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning. Methods Mol Biol. 2004; 265:131-158.
11. Pillai RS, Bhattacharyya SN and Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007; 17(3):118-126.
12. Thai TH, Christiansen PA and Tsokos GC. Is there a link between dysregulated miRNA expression and disease? Discov Med. 2010; 10(52):184-194.
13. German MA, Pillay M, Jeong DH, Hetawal A, Luo S, Janardhanan P, Kannan V, Rymarquis LA, Nobuta K, German R, De Paoli E, Lu C, Schroth G, Meyers BC and Green PJ. Global identification of microRNA-target RNA pairs by parallel analysis of RNA ends. Nat Biotechnol. 2008; 26(8):941-946.
14. Yang Y, Chaerkady R, Kandasamy K, Huang TC, Selvan LD, Dwivedi SB, Kent OA, Mendell JT and Pandey A. Identifying targets of miR-143 using a SILAC-based proteomic approach. Mol Biosyst. 2010; 6(10):1873-1882.
15. Qian X, Yu J, Yin Y, He J, Wang L, Li Q, Zhang LQ, Li CY, Shi ZM, Xu Q, Li W, Lai LH, Liu LZ and Jiang BH. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013; 12(9):1385-1394.
16. Akao Y, Nakagawa Y, Iio A and Naoe T. Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk Res. 2009; 33(11):1530-1538.
17. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28(10):1385-1392.
18. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN and Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009; 460(7256):705-710.
19. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S and Miyazono K. Modulation of microRNA processing by p53. Nature. 2009; 460(7254):529-533.
20. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr R, Hartmann A, Wullich B and Grasser F. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010; 8(4):529-538.
21. Zhang H, Cai X, Wang Y, Tang H, Tong D and Ji F. microRNA-143, downregulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010; 24(5):1363-1369.
22. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296(5573):1655-1657.
23. Shaw LM. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol. 2001; 21(15):5082-5093.
24. Tsurushima H, Tsuboi K, Yoshii Y, Ohno T, Meguro K and Nose T. Expression of N-ras gene in gliomas. Neurologia medico-chirurgica. 1996; 36(10):704-708.
25. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH and Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 2004; 18(1):103-112.
26. Cole AL, Subbanagounder G, Mukhopadhyay S, Berliner JA and Vora DK. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arteriosclerosis, thrombosis, and vascular biology. 2003; 23(8):1384-1390.
27. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL and El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010; 116(12):2974-2983.
28. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE and Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013; 110(10):4015-4020.
29. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB and Newcomb EW. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Laboratory investigation; a journal of technical methods and pathology. 2006; 86(12):1221-1232.
30. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA and Jensen RL. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(8):2441-2448.
31. Chen LF and Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004; 5(5):392-401.
32. Naugler WE and Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008; 18(1):19-26.
33. Rayet B and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999; 18(49):6938-6947.
34. Ghosh S and Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002; 109 Suppl:S81-96.
35. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007; 8(1):49-62.
36. Yadav V and Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog. 2011; 50(5):346-352.
37. Lee SH, Son MJ, Oh SH, Rho SB, Park K, Kim YJ, Park MS and Lee JH. Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res. 2005; 65(1):137-148.
38. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6-7.
39. Barbacid M. ras genes. Annu Rev Biochem. 1987; 56:779-827.
40. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, Li X, Ma J and Li G. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journal of cell science. 2011; 124(Pt 17):2997-3005.
41. Lo HW. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Current cancer drug targets. 2010; 10(8):840-848.
42. Tilch E, Seidens T, Cocciardi S, Reid LE, Byrne D, Simpson PT, Vargas AC, Cummings MC, Fox SB, Lakhani SR and Chenevix Trench G. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast cancer research and treatment. 2014; 143(2):385-392.
43. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17):4682-4689.
44. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-732.
45. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333(26):1757-1763.
46. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H and Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009; 113(2):249-255.
47. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J and Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008; 123(2):372-379.
48. Siemens H, Jackstadt R, Kaller M and Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 4(9):1399-1415.
49. Asuthkar S, Velpula KK, Chetty C, Gorantla B and Rao JS. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 2012; 3(11):1439-1454.
50. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ and Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005; 33(20):e179.
51. Wang X. A PCR-based platform for microRNA expression profiling studies. RNA. 2009; 15(4):716-723.
52. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604-4613.
53. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R and Croce CM. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010; 107(49):21098-21103.
54. Liu LZ, Zheng JZ, Wang XR and Jiang BH. Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. Cancer Res. 2008; 68(19):8183-8188.